Country Information


Mali

 
HIV prevalence 15-49, 2007/2008 1.5%
Tuberculosis death rate 74/100,000 population
Malaria death rate (children under 5) 2,046/100,000 population
 
   
             
     
  Mali, a landlocked nation of 12 million located in West Africa, has so far escaped the worst of the HIV/AIDS epidemic that is devastating so much of sub-Saharan Africa. While recurrent yellow fever, meningitis, cholera and measles epidemics are a threat to public health, only 1.7 percent of Malians have been infected with HIV. Relatively moderate rates of internal and external migration, and Islamic social and sexual mores (90 percent of Malians are Muslim) may partially explain Mali’s low HIV incidence rate relative to other sub-Saharan nations.

Despite the low rate of HIV/AIDS infection in Mali today, USAID's Synergy project reported indicators that HIV could spread very rapidly. Less than 10 percent of Malian women know how to avoid AIDS, and only 2 percent of women use condoms to prevent transmission of HIV. A second factor is the high level of HIV in commercial sex workers; 52 percent of prostitutes tested in urban areas were HIV positive. A third area of concern is the seasonal migration of farm workers to and from Cote d’Ivoire, the West African country with the highest rate of HIV infection. Finally, the practice of female genital mutilation (FGM) is widespread, leaving the 90 percent of the female population having undergone FGM at greater risk for HIV.

Mali’s current low rate of HIV prevalence is in part due to political commitment at the top. Former President Alpha Oumar Konare (later elected head of the African Union) appeared on television to promote the use of condoms to prevent the spread of HIV/AIDS. The social marketing of condoms, a typical part of HIV prevention programs, has been complicated by Mali’s extreme poverty and the opposition and criticism of Muslim clerics and conservative politicians.

Mali reported TB detection, notification and treatment information to the WHO in 2000, but did not report data in 2001. The United Nations Statistics Division reports that in 2000 Mali had 235 TB cases per 100,000, and 56 TB deaths per 100,000. The DOTS detection rate that year was 14 percent, and the successful treatment rate in 1999 was 68 percent.

Malaria is endemic throughout Mali; if malaria prevalence has remained constant since the United Nations Statistics Division's last reported data in 1998, Mali has approximately 440,000 reported malaria cases each year. More than 10 percent of those cases are fatal. USAID has reported that an estimated 85 percent of pregnant women in Mali contract malaria. Reducing this statistic is a major objective of USAID's country health program.

Sources: Synergy Project; BBC country profile; WHO Report 2003: Global Tuberculosis Control; United Nations Statistics Division; World Bank; USAID mission in Mali

 
           
             
  In 1998 Mali's government prepared a ten year strategic plan for the health sector, to be supported by a World Bank Sector Investment Program (SIP). The SIP contains four major components:
  • Expanding and improving the network of community health centers that provide primary health care for most Malians.
  • Providing management and technical training for health professionals.
  • Increasing affordability of health care through insurance and cost-sharing programs.
  • Improving the technical capabilities and cost efficieny of government hospitals.

In the 1990s the World Bank convinced Mali's government to end the monopoly on pharmaceuticals held by Pharmacie Populaire du Mali (PPM). This has had the beneficial effect of cutting drug prices in Mali by as much as 80 percent. According to the World Bank, while the government of Mali preserved PPMs monopoly status, PPM restricted the availability of generic drugs, inflated prices, and padded its payroll. The introduction of generic drugs and a competing NGO drug distributor has led to the reduced drug prices. Mali is also one of 13 nations taking part in the UNAIDS Accelerating Access Initiative (AAI), allowing it to purchase HIV/AIDS drugs from pharmaceutical companies at reduced prices.

Sources: World Bank, USAID, Centre de Cooperation Internationale en Santé et Développement (CCISD)

 
           
             
 
Total population. mid-2009 13.0 (millions)
HIV prevalence 15-49, 2007/2008 1.5%
Tuberculosis death rate 74/100,000 population
Prevalence of tuberculosis per 100,000 population, 2000 595
Prevalence of tuberculosis per 100,000 population, 2004 578
% Tuberculosis detection rate under DOTS, 2004 19
% Tuberculosis treatment success rate under DOTS, 2003 65
Malaria death rate (children under 5) 2,046/100,000 population
GNI PPP Per Capita, 2008 1,090 (US$)
Life expectancy at birth 48 years
Infant mortality rate 110/1,000 live births
Total fertility rate 6.0 per woman
Crude birth rate 43/1,000 population
Crude death rate 15/1,000 population
Adult male literacy level 32% (pct. 15+ literate)
Adult female literacy level 17% (pct. 15+ literate)
Contraceptive prevalence rate, modern methods 6% of women in union
Estimated number of people living with HIV: Adults and Children, 2005 130,000
Estimated number of people living with HIV: Adults and children, end 2003 140,000
Estimated number of people living with HIV: Adults and children, end 2001 130,000
Estimated number of people living with HIV: Adults (15+), 2005 110,000
Estimated number of people living with HIV: Adults (15-49), end 2003 120,000
Estimated number of people living with HIV: Adults (15-49), end 2001 120,000
Estimated number of people living with HIV: Adults (15-49) rate (%), 2005 1.9%
Estimated number of people living with HIV: Adults (15-49) rate (%), 2003 1.9%
Estimated number of people living with HIV: Women (15+), 2005 66,000
Estimated number of people living with HIV: Women 15-49, end 2003 71,000
Estimated number of people living with HIV: Women 15-49, end 2001 65,000
Estimated number of people living with HIV: Children (0-14), 2005 16,000
Estimated number of people living with HIV: Children (0-14), end 2003 13,000
Estimated number of people living with HIV: Children (0-14), end 2001 12,000
Estimated number of AIDS deaths: Adults and children, 2005 11,000
AIDS deaths in adults and children, end 2003 12,000
AIDS deaths in adults and children, end 2001 11,000
Estimated number of orphans due to AIDS: Children (0-17), 2005 94,000
Orphans due to AIDS (0-17), living 2003 75,000
Orphans due to AIDS (0-17), living 2001 59,000
% Women (15-49), currently married or living with a partner, who have ever discussed AIDS prevention with their husband or partner 20%

Demographic data contained in this section was obtained from the following sources: The Population Reference Bureau’s 2009 World Population Data Sheet was used for total population, life expectancy at birth, infant mortality, fertility, birth rate, death rate, % of married women 15-49 using modern methods of contraception, % of population 15-49 with HIV/AIDS in 2007/2008, and the GNI PPP per capita (2008). Literacy rates were found in the Population Reference Bureau’s publication 2005 Women of Our World. HIV prevalence data for 2001 and 2003 was obtained from the UNAIDS Barcelona 2002 report; HIV prevalence and orphan data for 2005 was obtained from the UNAIDS Report on the Global AIDS Epidemic 2006. Data on the % women who have discussed AIDS prevention with their husband or partner can be found in ORC Macro and USAID’s Women’s Lives and Experiences: Changes in the Past Ten Years (Research Findings from the Demographic and Health Surveys). Childhood malaria mortality data was accessed in 2003 from the United Nations Statistics Divisions’ Millennium Indicators. Tuberculosis data was obtained from the United Nations Statistics Division’s Millennium Indicators: MDGInfo 2006. In some cases information was unavailable.

 
           
             
  Mali spends about 4 percent of its gross domestic product on health; about half of that is spent within the public sector. In terms of health personnel, there are about 4 doctors, 13 nurses, 3 midwives, and 0.1 dentists per 10,000 persons. There is one medical school. Between 1995 and 1998 300 new community health centers were built with assistance from the World Bank, raising the proportion of Malians living within 15 kilometers of a health facility from 17 percent to 39 percent. About half of the nation’s health centers are run by the central government. Chronic staffing problems, especially in remote regions, have meant that some health centers have gone over a year without a nurse or doctor on staff.

The health infrastructure in the northern half of the country, which extends into the Sahara Desert, has been and continues to be much weaker than in the southern region and along the Niger River.

The World Bank reports that the average Malian receives care from the formal health sector only 0.16 times per year. This low level of utilization is a result of several factors, including inability to pay for services, inaccessibility of health facilities, and poor outreach.

Sources: World Bank, World Health Organization, Roll Back Malaria.

 
           
             
 

University of Mali, Malaria Research and Training Center

Field and laboratory studies of drug resistant malaria in West Africa are being conducted by the Ecole Nationale de Medicine et de Pharmacie at the University of Mali. Collaborators include the University of Maryland, NIH, and research institutions in Benin and Guinea.

The Malaria Research and Training Center (MRTC) at the University of Mali in Bamako is the most important medical research facility in the country. MRTC’s mission includes pharmaceutical research, especially research in developing a vaccine for malaria. NIAID works closely with the MRTC. Secretary of State Colin Powell’s visit to Mali in summer 2001 included a brief visit to the MRTC.

Tulane University and the Ecole Nationale de Medicine et de Pharmacie at the University of Mali worked with the Center for Health Applications of Aerospace Related Technologies (CHAART) of the Earth Science Division of NASA to use satellite imagery to better understand the epidemiology of malaria in Mali. Researchers from Tulane are also conducting epidemiological studies on the ground in two villages where the malaria parasite is endemic for about half the year. Researchers hope to identify factors that lead to severe illness in some children when the malaria parasite is present in the bloodstream of virtually the entire population.

Sources: MIM, Tulane University

 
           
             
 

Entity

Project Title

Diseases

Primary Category

Secondary Category

NIH Epitope Driven HIV Vaccine Development AI50528-01A1 HIV/AIDS Drug Development  
  (P.I. DE GROOT, ANNE S. 2004-2007) This goal of this project is to support a collaboration between researchers in Bamako, Mali and the TB/HIV...

NIH A Cohort Observational Study to Assess the Virologic Response to Standard HIV Treatment in Bamako, Mali HIV/AIDS Drug Development  
  National Institute of Allergy and Infectious Diseases, University of Bamako. Virologic response to standard HIV treatment in patients in Mali will...

NIH Phase 1, Randomized, Double-Blind, Dose Escalating Study of the Safety, Reactogenicity, and Immunogenicity of the AMA1-C1/Atthydrogel+CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Children in Malaria Drug Development Prevention
  National Institute of Allergy and Infectious Diseases. This trial will test the safety and efficacy of the candidate vaccine for the prevention of...

NIH Phase 1 Study of the Safety and Immunogeniity of BSAM-2/Alhydrogel® +CPG7909, An Asexual Blood Stage Vaccine for Plasmodium Malaria in Adults in the US and Mali Malaria Drug Development  
  National Institue of Allergy and Infectious Diseases, Johns Hopkins University, Malaria Research and Training Center, Bamako. This is a Phase 1...

NIH Phase 1 Pediatric FMP2.1/AS02A Trial in Mali Malaria Drug Development Prevention
  This trial will evaluate the safety and reactogenicity of a new malaria vaccine for children between the ages of 1 and 6. Three different dose...

NIH Phase 2 FMP2.1 Trial in Mali Malaria Drug Development Prevention
  National Institute of Allergy and Infectious Diseases. This study will enroll 400 children in a randomized, controlled clinical trial desgined to...

NIH Malaria Vaccine Development Unit (MVDU) Malaria Drug Development  
  (PI: Allan Saul. 2003) The MVDU has developed six malaria vaccine candidates and currently has three of them in Phase I trials in...

NIH Migration For Work, Mental Health And Aids In Mali HIV/AIDS Epidemiology  
  (P.I. SCHOOLER, CARMI 2003) In collaboration with the Centre Regional de Medecine Traditionnelle in Bandiagara Mali, this project investigates how...

NIH Clinical Correlates of Immune Reconstitution in Advanced HIV HIV/AIDS,Tuberculosis Epidemiology  
  (PI: Michael Polis. 2003) A component of this study is to investigate, in collaboration with the University of Mali, CD4 + T cell responses to TB in...

NIH Genomics of mosquito resistance to Plasmodium Malaria Epidemiology  
  (VERNICK, KENNETH D. 1998-2008) This project is a competing continuation proposal for the four-year project #AI42361, previously entitled,...

NIH Coinfection with Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Malaria Epidemiology Capacity
  National Institute of Allergy and Infectious Diseases. This study will examine the impact of co-infection with Plasmodium Falciparum and Wuchereria...

NIH Malaria Incidence in Infants in Bancoumana, Mali Malaria Epidemiology  
  National Institute of Allergy and Infectious Diseases. This study is designed to determine the burden of malaria in infants in rural Mali. The...

NIH Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria Malaria Epidemiology General
  National Heart, Lung, and Blood Institute with Tulane University and University of Bamako. Malaria-free children, children who are asymptomatic but...

NIH Immunologic Interaction of Schistosomiasis and Acute Malaria Malaria Epidemiology Drug Development
  (PI: Kirsten Lyke. 2002-2006.) Conflicting evidence exists as to whether chronic schistosomiasis is an ameliorating factor in malaria infections, or...

NIH Genetics of Gambiae Susceptibility to Plasmodium Malaria Epidemiology  
  (PI: Kenneth Vernick. 1998-2003.) The study aims to identify naturally occurring mosquito mechanisms that affect the development of Plasmodium...

NIH Population genomics of Mosquito An. gambiae in Africa Malaria Epidemiology Prevention
  (PI: Gregory Lanzaro. 1996-2007.) This study examines population size, patterns of gene flow and breeding stucture for the populations of mosquito...

NIH Profiling Immunological Parameters in the Cord Blood of Neonates Exposed to Plasmodium Falciparum in Utero Malaria Epidemiology Capacity
  National Institute of Allergy and Infectious Diseases with the Malaria REsearch and Training Center, Mali. The investigators will collect cord blood...

NIH Congenital and Neonatal Malaria in Mali Malaria Epidemiology  
  Blood samples from infants born prior to the 37th week of pregnancy and infants aged 0-28 days admitted for inpatient care will be tested for...

NIH Studies of Innate and Acquired Resistance to P. Falciparum Malaria in Mali Malaria Epidemiology Capacity
  National Institute of Allergy and Infectious Diseases. This study will examine the characteristics of blood samples to determine whether...

NIH Niono Irrigation Project and Malaria: A Computer Model Malaria Prevention Epidemiology
  (PI: Charles Taylor. 2002-2007.) Most irrigation projects in malarial regions result in an increase in mosquito breeding grounds and populations;...

NIH Core - International HIV/AIDS Capacity  
  (PI: King Holmes. 2002) The University of Washington’s International Sub-core of the CFAR Clinical...

NIH Establishment of Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali Malaria Capacity  
  National Institute of Allergy and Infectious Diseases. Serum samples will be collected from healthy adult volunteers in Mali and used to study...

NIH Malaria Studies in Africa Malaria Capacity Drug Development
  (PI: Robert Gwadz. 2003) An NIH grant supporting the establishment of the Malaria Research and Training Center (MRTC) in Mali. MRTC studies include...

NIH Malaria Research Training in Mali Malaria Capacity  
  (PI: Christopher Plowe. 2000-2005.) A collaborative effort between the University of Maryland and the MRTC at the University of Mali to provide...

NIH Informatics Training for Global Health in Mali HIV/AIDS,Tuberculosis,Malaria General  
  (P.I. 2004-2009 MATHER, FRANCES J.) The project's goal is the training of African scientists in informatics, research methods and global health.

NIH Collection of Tissue Specimens in Mali, West Africa, for HIV and Tuberculosis Research HIV/AIDS,Tuberculosis General  
  National Institute of Allergy and Infectious Diseases. Blood and sputum samples will be collected from adults in an effort to determine normal...

NIH Immune Response to Mycobacterium Tuberculosis Infection Tuberculosis General  
  National Institute of Allergy and Infectious Diseases. Participants in Mali and the United States were enrolled in this study, designed to examine...

Other US Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine for the Treatment of Uncomplicated P. Falciparum Malaria in Children in Africa Malaria Drug Development  
  Pfizer. This study seeks to compare and contrast two different treatment regimens for malaria in chldren: a combination of azithromycin and...

Other US Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa Malaria Drug Development  
  (Pfizer Study) This trial will enroll 233 participants in Kenya, Malawi, Uganda, and Zambia in an effort to compare the effects of a treatment...

Other US Chlorproguanil-Dapsone in Pregnant Women Malaria Drug Development Prevention
  CDC. (PIs: Robert Newman, Kassoum Kayentao, Feiko ter Kuile, Ogobara Doumbo, Monica Parise) Sixty-six pregnant women presenting with P. falciparum...

Other US Antimalarial Drug Resistance in Mali Malaria Drug Development  
  CDC (PIs: Robert Newman, Kassoum Kayentao, John Barnwell, Ogobara Doumbo). This study will examine the impact of antimalarial drugs and drug...

Other US USAID HIV/AIDS,Tuberculosis,Malaria General  
  USAID supports child survival and reproductive health programs at the level of primary care. Altogether the United States contributed about...

International ATAQ Easy: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria Malaria Drug Development  
  Sanofi-Aventis (Study Director: Valérie Lameyre). This study will compare and contrast the efficacy of three treatment regimens for malaria in...

International Efficacy and Safety of the Pediatric Formulation of Artemether-Lumefantrine in Children with Uncomplicated P. Falciparum Malaria Malaria Drug Development  
  Novartis. This trial is designed to determine the safety and effectiveness of a pediatric regimen of artemether-lumefantrine when children ages 12...

International Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) for Uncomplicated Malaria Malaria Drug Development  
  GlaxoSmithKline, Medicines for Malaria Venture, and World Health Organization. This phase III study of the efficacy and safety of a malaria...

International Randomized Trial of Erythropoietin During Cerebral Malaria (EPOMAL) Malaria Drug Development  
  Claude Bernard University, Gabriel Toure Hospital (PI: Stephane Picot). 120 patients between the ages of 6 months and 15 years who have been...

International A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity from Malaria in African Children (IPTc/ITNs) Malaria Prevention  
  London School of Hygiene and Tropical Medicine; Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso; Malaria Research and...

International Seasonal Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine in Children in Mali Malaria Prevention  
  University of Bamako, World Health Organization (Study Director: Ogobara Doumbo; PI: Alassane Dicko). Children between the ages of 6 months and...

International Intermittent Preventive Treatment in Infant in Mali Malaria Prevention Capacity
  University of Bamako, UNICEF (Study Director: Ogobara Doumo; PI: Alassane Dicko). In this study, researchers evaluted the impact of administering...

International World Bank HIV/AIDS,Tuberculosis,Malaria General  
  The World Bank works with the Government of Mali to achieve the following goals:
  • To increase community participation in the
...

International Switzerland HIV/AIDS,Tuberculosis,Malaria General  
  Switzerland allocated 12.1 million Swiss francs to bilateral assistance and humanitarian aid for Mali in 2001.

Priorities for Swiss aid for...

International UN Agencies HIV/AIDS,Tuberculosis,Malaria General  
  Several organizations under the UN umbrella are active in strengthening Mali's efforts to contain both HIV/AIDS and TB. Specific...

International CIDA (Canada) HIV/AIDS,Tuberculosis General  
  Canadian aid to Mali includes several projects in the health sector:
  • CIDA's AIDS 3 project in Mali will continue its work in preventing the
...

International France (CFD) HIV/AIDS,Tuberculosis,Malaria General  
  French aid in Mali is aimed at:
  • Strengthening operations of health centers.
  • Supporting hospital referral services.
  • Providing
...

International Germany (DSE) HIV/AIDS,Tuberculosis,Malaria General  
  Mali is the top recipient of German foreign aid, receiving DM 85 million from Deutsche Stiftung fur internationale Entwicklung (DSE - the German...

International Belgium HIV/AIDS,Tuberculosis,Malaria General  
  The Belgian government collaborates with UNFPA in providing aid to Mali, and also provides multi/bilateral funding for medical programs in four...

International Global Fund for AIDS, Tuberculosis and Malaria (GFATM) Malaria General  
  In 2002 the Global Fund approved slightly more than $2 million in funding for anti-malarial work in Mali. The Ministry of Health of the Government...

NGO MIM/TDR Grants for Malaria Research Malaria Epidemiology  
  In 2002 a Multilateral Initiative on Malaria (MIM)/TDR Task Force awarded a grant of $69,000 to support a MIM/TDR Antimalarial Drug Resistance...

NGO Bristol Myers Squibb: Secure the Future Programs HIV/AIDS General  
  In March, 2001, the Bristol Myers Squibb (BMS) Company, through Secure the Future, provided $15 million for...

Foundation Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients Malaria Drug Development  
  Medicines for Malaria Venture, Shin Poong Pharmaceuticals (Study Director: Claude Oeuvray; PIs: Alfred Tiono, Antoinette Tshefu Kitoto, Louis...

 
           
             
 
  1. ESTHER, a European AIDS initiative launched in Rome in 2002 with support from France, Italy, Luxembourg and Spain, aims to build partnerships between European hospitals and health care systems in the developing world. Mali is one of the nations in which ESTHER plans to begin its work.

    Source: ESTHER Network fact sheet

  1. The Global Fund has approved roughly $23.4 million in funding to combat HIV/AIDS in Mali. $2.7 million has been approved to fight tuberculosis. The grant agreements have yet to be signed.

    Source: Global Fund agreements and disbursements spreadsheet

 
           



Home || HIV/AIDS || Tuberculosis || Malaria || Advanced Search || Links || Contact Us

Last site update: October 28, 2009

For questions, or to report problems with this site, please contact the Webmaster.

Disclaimer